Document:

EX-10.2

 Exhibit 10.2 

AMENDMENT NO. 1 
 TO THE

 INVESTMENT MANAGEMENT TRUST AGREEMENT 

This Amendment No. 1 (this “Amendment”), dated as of December 20, 2022, to the Investment Management Trust
Agreement (as defined below) is made by and between Phoenix Biotech Acquisition Corp. (the “Company”) and Continental Stock Transfer & Trust Company, as trustee (“Trustee”). All terms used but not defined
herein shall have the meanings assigned to them in the Trust Agreement. 
 WHEREAS, the Company and the Trustee entered into an
Investment Management Trust Agreement dated as of October 5, 2021 (the “Trust Agreement”); 
 WHEREAS,
Section 1(i) of the Trust Agreement sets forth the terms that govern the liquidation of the Trust Account under the circumstances described therein; and 

WHEREAS, at an special meeting of the Company held on December 16, 2022, the Company’s stockholders approved (i) a
proposal to amend the Company’s amended and restated certificate of incorporation (the “A&R COI”) to (a) extend the date by which the Company has to consummate a business combination from January 8, 2023 to
April 8, 2023 (the “First Expiration Date”) and (b) provide the board of directors of the Company (the “Board”) the right to further extend such date by which the Company has to consummate a business
combination up to three times for additional one month each time, from April 8, 2023 to May 8, 2023, June 8, 2023 or July 8, 2023 (the latest date to which such deadline is extended, the “Later Expiration
Date”); and (ii) a proposal to amend the Trust Agreement to (a) extend the date by which the Company has to consummate a business combination from January 8, 2023 to the First Expiration Date or the Later Expiration Date,
subject to the terms and conditions of the A&R COI, as amended, and (b) allow the Company to withdraw from the trust account and distribute to the Company the amount of interest earned on the Property to be used for the payment of any
applicable taxes. 
 NOW THEREFORE, IT IS AGREED: 

1. Section 1(i) of the Trust Agreement is hereby amended and restated in its entirety as follows: 

“(i) Commence liquidation of the Trust Account only after and promptly after (x) receipt of, and only in accordance with, the terms
of a letter from the Company (“Termination Letter”) in a form substantially similar to that attached hereto as either Exhibit A or Exhibit B, as applicable, signed on behalf of the Company by its
Chief Executive Officer, President, Chief Financial Officer or Chairman of the board of directors (the “Board”) or other authorized officer of the Company (and in the case of Exhibit A, signed by the
Representative), and complete the liquidation of the Trust Account and distribute the Property in the Trust Account, including any amounts representing interest earned on the Trust Account, less interest previously released to, or reserved for use
by, the Company in an amount up to $100,000 to pay dissolution expenses (as applicable) and less any other interest released to, or reserved for use by, the Company to pay franchise and income taxes as provided in this Agreement only as directed in
the Termination Letter and the other documents referred to therein, or (y) upon the date which is the later of April 8, 2023 or, if the Board elects to extend such date in accordance with the terms and conditions of the Company’s
Amended and Restated Certificate of Incorporation for additional one month periods, to the date to which such deadline is extended, which shall not be later than July 8, 2023, as applicable; provided that upon
each one-month extension of the period of time to consummate an initial Business Combination, Phoenix Biotech Sponsor, LLC (the “Sponsor”) (or one or more of its affiliates,
members or third-party designees) (the “Lender”) will deposit into the Trust Account: (I) for the first such monthly extension, $100,000; (II) for the second such monthly extension, $125,000; and (III) for the third
such monthly extension, $150,000, for an aggregate deposit of up to $375,000; and (2) such later date as may be approved by the Company’s stockholders in accordance with any further amendment of the Company’s Amended and Restated
Certificate of Incorporation (“Termination Date”), if a Termination Letter has not been received by the Trustee prior to such date, in which case the Trust Account shall be liquidated in accordance with the procedures set
forth in the Termination Letter attached as Exhibit B and the Property in the Trust Account, including any amounts representing interest earned on the Trust Account, less interest previously released to, or reserved for use by, the
Company in an amount up to $100,000 to pay dissolution expenses (as applicable) and less any other interest released to, or reserved for use by, the Company to pay franchise 

 
and income taxes, shall be distributed to the Public Stockholders of record as of such date. If the Company completes the Business Combination (as defined below), it will, at the option of the
Lender, repay the amounts loaned under the promissory note(s) or convert a portion or all of the amounts loaned under such promissory note(s) into units at a price of $10.00 per unit, which units will be identical to the private placement units
issued to the Sponsor at the time of the Offering. If the Company does not complete the Business Combination by the applicable Termination Date, such promissory notes will be repaid only from funds held outside of the Trust Account. The Trustee
agrees to serve as the paying agent of record (“Paying Agent”) with respect to any distribution of Property that is to be made to the Public Stockholders and, in its separate capacity as Paying Agent, agrees to distribute
such Property directly to the Company’s Public Stockholders in accordance with the terms of this Agreement and the Company’s Certificate of Incorporation in effect at the time of such distribution;” 

2. A new Section 1(m) shall be added as follows: 

“(m) Upon written request from the Company, which may be given from time to time in a form substantially similar to that attached hereto
as Exhibit E (an “Extension Letter”), at least five business days prior to the applicable Termination Date (as may be extended in accordance with Section 1(i)), signed on behalf of the
Company by an executive officer, and receipt of the dollar amount specified in the Extension Letter on or prior to such termination date (if and as applicable), follow the instructions set forth in the Extension Letter.” 

4. The term “Property” shall be deemed to include any Extension Fee paid to the Trust Account in accordance with the terms of
the Amended and Restated Certificate of Incorporation and the Trust Agreement. 
 5. A new Exhibit E of the Trust Agreement is hereby
added as follows: 
 [Letterhead of Company] 

[Insert date] 
 Continental Stock
Transfer & Trust Company 
 1 State Street, 30th Floor 

New York, New York 10004 
 Attn: Francis Wolf and Celeste Gonzalez

 Re: Trust Account — Extension Letter 

Dear Mr. Wolf and Ms. Gonzalez: 

Pursuant to paragraphs 1(j) and 1(m) of the Investment Management Trust Agreement between Phoenix Biotech Acquisition Corp.
(“Company”) and Continental Stock Transfer & Trust Company (“Trustee”), dated as of October 5, 2021, as amended by Amendment No. 1 dated
                    , 2022 (“Trust Agreement”), this is to advise you that the Company is extending the time available
in order to consummate a Business Combination with the Target Business for an additional one month, from                      to
                     (the “Extension”). Capitalized words used herein and not otherwise defined shall have the
meanings ascribed to them in the Trust Agreement. 
 This Extension Letter shall serve as the notice required with respect to Extension
prior to the applicable deadline. 
 [IF APPLICABLE: In accordance with the terms of the Trust Agreement, we hereby authorize you to deposit
the Extension Fee, which will be wired to you, into the Trust Account investments upon receipt.] 

 
			
	Very truly yours,
	
	Phoenix Biotech Acquisition Corp.
		
	By:	 	  

		 	Name:
		 	Title:

  

	cc:	 Cantor Fitzgerald & Co. 

6. All other provisions of the Trust Agreement shall remain unaffected by the terms hereof. 

7. This Amendment may be signed in any number of counterparts, each of which shall be an original and all of which shall be deemed to be one
and the same instrument, with the same effect as if the signatures thereto and hereto were upon the same instrument. A facsimile signature or electronic signature shall be deemed to be an original signature for purposes of this Amendment. 

8. This Amendment is intended to be in full compliance with the requirements for an Amendment to the Trust Agreement as required by
Section 6(c) of the Trust Agreement, and every defect in fulfilling such requirements for an effective amendment to the Trust Agreement is hereby ratified, intentionally waived and relinquished by all parties hereto. 

9. This Amendment shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect
to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. 
 [signature page
follows] 

 IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to the
Investment Management Trust Agreement as of the date first written above. 
  

			
	CONTINENTAL STOCK TRANSFER & TRUST COMPANY, as Trustee
		
	By:	 	 /s/ Francis Wolf

		 	Name: Francis Wolf
		 	Title: Vice President
	
	PHOENIX BIOTECH ACQUISITION CORP.
		
	By:	 	 /s/ Chris Ehrlich

		 	Name: Chris Ehrlich
		 	Title: Chief Executive OfficerEX-4.1

 Exhibit 4.1 

AMENDED AND RESTATED 

AMENDMENT NO. 1 TO WARRANT AGREEMENT 

This Amended and Restated Amendment (this “Amendment”) is made as of December 20, 2022, by and between Genius Sports
Limited, incorporated under the laws of Guernsey as a non-cellular company limited by shares (the “Company”), and Continental Stock Transfer & Trust Company, a New
York corporation, as warrant agent (the “Warrant Agent”), and constitutes an amendment to that certain Warrant Agreement, dated as of August 13, 2020 (as amended, the “Existing Warrant
Agreement”), between dMY Technology Group, Inc. II (“dMY”) and the Warrant Agent, which was assumed by the Company pursuant to that certain Warrant Assumption Agreement dated as of April 20, 2021, by and
among dMY, the Company, and the Warrant Agent. Capitalized terms used but not otherwise defined in this Amendment shall have the meanings given to such terms in the Existing Warrant Agreement. 

WHEREAS, Section 9.8(iii) of the Existing Warrant Agreement provides that the Company and the Warrant Agent may amend, subject to certain
conditions provided therein, the Existing Warrant Agreement without the consent of Registered Holders as the parties may deem necessary or desirable and in a manner that the parties deem shall not adversely affect the rights of the Registered
Holders; 
 WHEREAS, on November 18, 2022, the Company and Warrant Agent entered into an amendment to the Existing Warrant Agreement
(“Prior Amendment No. 1”) to provide Registered Holders with the option to exercise their warrants on a cashless basis, with the effectiveness of Prior Amendment No. 1 conditioned on the
Company receiving requisite warrant holder approval to amend the Exercise Period of the warrants; and 
 WHEREAS, the Company desires to
amend and restate Prior Amendment No. 1 to provide Registered Holders with the option to exercise their warrants on a cashless basis, on the terms and subject to the conditions set forth herein in lieu of the terms and conditions set forth in
Prior Amendment No. 1. 
 NOW, THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree to amend the Existing Warrant Agreement as set forth herein. 

1. Amendment of Existing Warrant Agreement. The Existing Warrant Agreement is hereby amended by adding a new Section 3.3.1(f) (the
“Amendment”): 
 (f) on a cashless basis, by directing the Company to issue such number of Ordinary
Shares over which Warrants are being exercised by the Registered Holder as is equal (but rounded up to the nearest whole number of Ordinary Shares) to the quotient obtained by dividing (x) the aggregate Warrant Price by (y) the
“Fair Market Value” (as defined in this subsection 3.3.1(f)) to a subsidiary of the Company, which will pay the aggregate Warrant Price in cash to the Company on the Registered Holder’s behalf. Solely for purposes
of this subsection 3.3.1(f)), the “Fair Market Value” shall mean the volume-weighted average price of the Ordinary Shares for the one-trading day period on the New York Stock
Exchange on the second trading day prior to the Expiration Date (as such term is defined in the Company’s amended Registration Statement on Form F-4 (File
No. 333-268457) filed on December 20, 2022). Should a Registered Holder elect to exercise their Warrants pursuant to this subsection 3.3.1(f), the Company will issue to the Registered Holder the balance
(if any) of the number of Ordinary Shares over which such Warrants are being exercised by the Registered Holder (after the payment of aggregate Warrant Price by, and the issue of Ordinary Shares to, the subsidiary of the Company pursuant to this
subsection 3.3.1(f)). 
 2. Effectiveness. The Company intends to file with the U.S. Securities and Exchange Commission a
registration statement on Form F-4 to solicit consents (the “Consent Solicitation”) from the Registered Holders to amend the Existing Warrant Agreement so that any warrants
not exercised by a holder thereof on or prior to the expiration date of the Consent Solicitation shall be exercised automatically on behalf of the holder on a cashless basis at an Exercise Price that is 76.6% of the volume-weighted average price for
the one-Trading Day period on the NYSE on the second Trading Day prior to the Expiration Date, or 0.234 Ordinary Shares per warrant, 10% less 

 
than the number of Ordinary Shares per Warrant to be received by holders that exercise cashlessly at the Reduced Exercise Price (as defined below) on or prior to the Expiration Date, on the first
Trading Day following the Expiration Date (as such term is defined in the Company’s amended Registration Statement on Form F-4 filed on December 20, 2022) (as it may be amended prior to the date
hereof, the “Warrant Expiration Amendment”). The “Reduced Exercise Price” means an exercise price that is 74% of the volume-weighted average price of the Ordinary Shares for the one-trading day period on the New York Stock Exchange on the date which is the second trading day prior to the Expiration Date (as such term is defined in the Company’s amended Registration Statement on Form F-4 (File No. 333-268457) filed on December 20, 2022) (if and only if such Reduced Exercise Price would be less than $11.50 per share). Unless waived by the Company,
this Amendment shall not come into effect until, and is conditioned on, the approval of the Warrant Expiration Amendment by the vote or written consent of holders of at least 50% of the outstanding Warrants. 

3. Miscellaneous Provisions. 

a) Severability. This Amendment shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall
not affect the validity or enforceability of this Amendment or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this
Amendment a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable. 
 b)
Applicable Law. The validity, interpretation, and performance of this Amendment and of the Warrants shall be governed in all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result
in the application of the substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim against it arising out of or relating in any way to this Amendment shall be brought and enforced in the courts of the
State of New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction
and that such courts represent an inconvenient forum. 
 c) Counterparts. This Amendment may be executed in any number of counterparts
(which may include counterparts delivered by any standard form of telecommunication) and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same
instrument. The words “execution,” “signed,” “signature,” and words of like import in this Amendment or in any other certificate, agreement or document related to this Amendment, if any, shall include images of manually
executed signatures transmitted by facsimile or other electronic format (including, without limitation, “pdf,” “tif” or “jpg”) and other electronic signatures (including, without limitation, DocuSign and AdobeSign). The
use of electronic signatures and electronic records (including, without limitation, any contract or other record created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect, validity and
enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent permitted by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State
Electronic Signatures and Records Act and any other applicable law, including, without limitation, any state law based on the Uniform Electronic Transactions Act or the Uniform Commercial Code. 

d) Effect of Headings. The section headings herein are for convenience only and are not part of this Amendment and shall not affect the
interpretation thereof. 
 e) Entire Agreement. The Existing Warrant Agreement, as modified by this Amendment, constitutes the entire
understanding of the parties and supersedes all prior agreements, understandings, arrangements, promises and commitments, whether written or oral, express or implied, relating to the subject matter hereof, and all such prior agreements,
understandings, arrangements, promises and commitments are hereby canceled and terminated. 
 [Signature Pages Follow] 

  
 2 

 IN WITNESS WHEREOF, each of the parties has caused this Amendment to be duly executed as of
the date first above written. 
  

	
	 GENIUS SPORTS LIMITED

	
	/s/ Nicholas Taylor
	Name: Nicholas Taylor
	Title: Chief Financial Officer
	
	 CONTINENTAL STOCK TRANSFER &
 TRUST
COMPANY, as Warrant Agent

	
	/s/ Michael Mullings
	Name: Michael Mullings
	Title: CCO

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]